Eli Lilly and Company (LLY)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Baqsimi Revenue	-	-	29.10M
Baqsimi Revenue Growth	-	-	-95.70%
Basaglar Revenue	658.20M	626.00M	676.90M
Basaglar Revenue Growth	5.14%	-7.52%	-7.06%
Humalog Revenue	2.07B	2.17B	2.32B
Humalog Revenue Growth	-4.37%	-6.74%	39.77%
Humulin Revenue	691.80M	705.00M	917.10M
Humulin Revenue Growth	-1.87%	-23.13%	7.63%
Jardiance Revenue	3.53B	3.43B	3.34B
Jardiance Revenue Growth	2.89%	2.73%	21.72%
Mounjaro Revenue	27.79B	22.97B	11.54B
Mounjaro Revenue Growth	20.99%	99.00%	123.51%
Trajenta Revenue	318.10M	318.00M	353.90M
Trajenta Revenue Growth	0.03%	-10.14%	-8.53%
Trulicity Revenue	4.10B	4.28B	5.25B
Trulicity Revenue Growth	-4.12%	-18.61%	-26.35%
Zepbound Revenue	15.39B	13.54B	4.93B
Zepbound Revenue Growth	13.65%	174.93%	2701.88%
Other Cardiometabolic Health Revenue	225.90M	189.00M	187.90M
Other Cardiometabolic Health Revenue Growth	19.52%	0.58%	31.31%
Cardiometabolic Health Revenue	54.77B	48.22B	29.52B
Cardiometabolic Health Revenue Growth	13.59%	63.34%	50.10%
Oncology Revenue	9.70B	9.38B	8.75B
Oncology Revenue Growth	3.42%	7.12%	31.45%
Immunology Revenue	5.36B	5.25B	4.39B
Immunology Revenue Growth	2.19%	19.44%	15.68%
Neuroscience Revenue	1.50B	1.39B	1.47B
Neuroscience Revenue Growth	7.96%	-5.59%	-48.81%
Other Product Revenue	917.70M	944.00M	903.00M
Other Product Revenue Growth	-2.79%	4.54%	-19.53%
Revenue (Other)	-900.00K	-	400.00K
Revenue (Total)	72.25B	65.18B	45.04B
Revenue (Total) Growth	10.85%	44.70%	32.00%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
US Revenue	47.11B	43.48B	30.38B
US Revenue Growth	8.35%	43.15%	39.39%
Europe Revenue	12.81B	11.56B	6.92B
Europe Revenue Growth	10.87%	67.01%	12.08%
Japan Revenue	2.30B	2.13B	1.81B
Japan Revenue Growth	7.91%	17.47%	8.51%
China Revenue	2.19B	1.95B	1.66B
China Revenue Growth	12.42%	17.50%	7.84%
Other Foreign Countries Revenue	7.83B	6.06B	4.27B
Other Foreign Countries Revenue Growth	29.29%	41.80%	44.98%
Revenue (Other)	-	-	400.00K
Revenue (Total)	72.25B	65.18B	45.04B
Revenue (Total) Growth	10.85%	44.70%	32.00%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Revenue Change due to Price	-6.00%	5.00%
Revenue Change due to Volume	50.00%	27.00%
Revenue Change due to FX	1.00%	-

Updated Apr 30, 2026. Data Source: Fiscal.ai.